CLAIMS

1. An immunity enhancing agent for cancer, comprising an anti-Allergin-1 antibody, an Allergin-1 binding protein or an Allergin-l-fusion protein as an active ingredient for use in the suppression of progress of, the suppression of recurrence of and/or the treatment of cancer.

2. Use of an Allergin-1 antagonist in the manufacture of an immunity enhancing agent for the treatment of cancer.

3. The agent according to claim 1, or the use according to claim 2, wherein the Allergin-1 antagonist suppresses immunosuppressive intracellular signalling of Allergin-1.

4. The agent or use according to claim 3, wherein the anti-Allergin-1 antibody is an anti-human Allergin-1 antibody.

5. The agent or the use according to claim 3 or claim 4, wherein the anti-Allergin-1 antibody is a monoclonal antibody.

6. The agent or the use according to claim 5, wherein the anti-Allergin-1 monoclonal antibody is of IgGi or IgG4 isotype.

7. The agent or the use according to claim 5 or claim 6, wherein the anti-Allergin-1 monoclonal antibody is an antibody fragment selected from the group consisting of Fab, Fab', Fv, scFv and (Fab')2 fragments.

8. The agent or the use according to any one of claims 5 to 7, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human antibody.

9. The agent or the use according to claim 5, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human anti-human Allergin-1 monoclonal IgGi or IgG4 antibody.

10. The agent or the use according to claim 3 or claim 4, wherein the anti-Allergin-1 antibody is an Allergin-1 multispecific antibody recognizing two or more different epitopes present on

one Allergin-1 molecule.

11. The agent or the use according to any one of claims 2 to 10, wherein the cancer is solid cancer or hematologic cancer.

12. The agent or the use according to claim 11, wherein the solid cancer is one or more selected from malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, renal cell cancer, clear cell renal cell cancer, breast cancer, ovarian cancer, ovarian clear eel adenocarcinoma, bone and soft tissue sarcoma, glioblastoma, gliosarcoma, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, hepatocellular cancer, esophageal cancer, pancreatic cancer, stomach cancer, urothelial cancer, prostate cancer, fallopian tube cancer, primary peritoneal cancer, pleural mesothelioma and myelo-proliferative syndrome.

13. The agent or the use according to claim 11, wherein the hematologic cancer is one or more selected from multiple myeloma, nonHodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukaemia and chronic myeloid leukaemia.

14. The agent or the use according to any one of claims 1 to 13, which is to be administered to a cancer patient unresponsive to an anti-cancer drug.

15. The agent or the use according to claim 14, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

16. The agent or the use according to claim 15, wherein the tumor immunotherapeutic agent is one or more selected from an antiPD-1 antibody, an anti-PD-Ll antibody, an anti-PD-L2 antibody, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-C>X40 antibody, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

17. The agent or the use according to claim 16, wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGBA317, STI-A1110 or AMP-514.

18. The agent or the use according to claim 16, wherein the anti-PD-Ll antibody is Atezo-lizumab, Avelumab, Durvalumab or BMS-936559.

19. The agent or the use according to claim 16, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab.

20. The agent or the use according to claim 16, wherein the PD-L2 fusion protein is AMP-224.

21. The agent or the use according to any one of claims 1 to 20, wherein one or more anti-cancer drugs are to be further administered.

22. The agent or the use according to claim 21, wherein the Allergin-1 antagonist and the anti-cancer drug in different preparations are to be administered.

23. The agent or the use according to claim 21, wherein the Allergin-1 antagonist and the anti-cancer drug in one preparation is to be administered.

24. The agent or the use according to any one of claims 21 to 23, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

25. The agent or the use according to claim 24, wherein the tumor immunotherapeutic agent is one or more selected from an antiPD-1 antibody, an anti-PD-Ll antibody, an anti-PD-L2 anti-body, a PD-Ll fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-0X4G anti-body, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

26. The agent or the use according to claim 25, wherein the anti-PD-' antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGBA317, STI-A1110 or AMP-514.

27. The agent or the use according to claim 25, wherein the anti-PD-Ll antibody is Atezolizumab, Avelumab or Durvalumab.

28. The agent or the use according to claim 25, wherein the anti-CTLA-4 antibody is Treme-limumab.

29. The agent or the use according to claim 25, wherein the PD-L2 fusion protein is AMP-224.

30. An Allergin-1 antagonist for use in enhancing the immunity against cancer in a cancer patient.